日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

ATR抑制剂ceralasertib通过调节肿瘤微环境增强癌症检查点免疫疗法的疗效。

Elizabeth L Hardaker # ,Emilio Sanseviero # ,Ankur Karmokar # ,Devon Taylor # ,Marta Milo ,Chrysis Michaloglou ,Adina Hughes ,Mimi Mai ,Matthew King ,Anisha Solanki ,Lukasz Magiera ,Ricardo Miragaia ,Gozde Kar ,Nathan Standifer ,Michael Surace ,Shaan Gill ,Alison Peter ,Sara Talbot ,Sehmus Tohumeken ,Henderson Fryer ,Ali Mostafa ,Kathy Mulgrew ,Carolyn Lam ,Scott Hoffmann ,Daniel Sutton ,Larissa Carnevalli ,Fernando J Calero-Nieto ,Gemma N Jones ,Andrew J Pierce ,Zena Wilson ,David Campbell ,Lynet Nyoni ,Carla P Martins ,Tamara Baker ,Gilberto Serrano de Almeida ,Zainab Ramlaoui ,Abdel Bidar ,Benjamin Phillips ,Joseph Boland ,Sonia Iyer ,J Carl Barrett ,Arsene-Bienvenu Loembé ,Serge Y Fuchs ,Umamaheswar Duvvuri ,Pei-Jen Lou ,Melonie A Nance ,Carlos Alberto Gomez Roca ,Elaine Cadogan ,Susan E Critichlow ,Steven Fawell ,Mark Cobbold ,Emma Dean ,Viia Valge-Archer ,Alan Lau ,Dmitry I Gabrilovich ,Simon T Barry

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

AZD5305(下一代高选择性 PARP1 抑制剂和捕获剂)的临床前表征

Giuditta Illuzzi #, Anna D Staniszewska #, Sonja J Gill #, Andy Pike, Lisa McWilliams, Susan E Critchlow, Anna Cronin, Stephen Fawell, Glen Hawthorne, Kunzah Jamal, Jeffrey Johannes, Emilyanne Leonard, Ruth Macdonald, Gareth Maglennon, Jenni Nikkilä, Mark J O'Connor, Aaron Smith, Harriet Southgate, 

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

通过急性 CDK9 抑制靶向 Bfl-1 可克服淋巴瘤中内在的 BH3 模拟物耐药性

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C Saeh, Stephen E Fawell, Ricky W Johnstone, Lisa Drew, Justin Cidado

Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy

设计和优化树状聚合物偶联的Bcl-2/x(L)抑制剂AZD0466,以提高其在癌症治疗中的治疗指数

Patterson, Claire M; Balachander, Srividya B; Grant, Iain; Pop-Damkov, Petar; Kelly, Brian; McCoull, William; Parker, Jeremy; Giannis, Michael; Hill, Kathryn J; Gibbons, Francis D; Hennessy, Edward J; Kemmitt, Paul; Harmer, Alexander R; Gales, Sonya; Purbrick, Stuart; Redmond, Sean; Skinner, Matthew; Graham, Lorraine; Secrist, J Paul; Schuller, Alwin G; Wen, Shenghua; Adam, Ammar; Reimer, Corinne; Cidado, Justin; Wild, Martin; Gangl, Eric; Fawell, Stephen E; Saeh, Jamal; Davies, Barry R; Owen, David J; Ashford, Marianne B

Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity

小分子AZD4635作为A2AR信号通路抑制剂,可恢复包括CD103+树突状细胞在内的免疫细胞功能,从而增强抗肿瘤免疫力。

Alexandra Borodovsky # ,Christine M Barbon # ,Yanjun Wang ,Minwei Ye ,Laura Prickett ,Dinesh Chandra ,Joseph Shaw ,Nanhua Deng ,Kris Sachsenmeier ,James D Clarke ,Bolan Linghu ,Giles A Brown ,James Brown ,Miles Congreve ,Robert Ky Cheng ,Andrew S Dore ,Edward Hurrell ,Wenlin Shao ,Richard Woessner ,Corinne Reimer ,Lisa Drew ,Stephen Fawell ,Alwin G Schuller ,Deanna A Mele

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

BRD4抑制剂与PARP抑制剂通过诱导同源重组缺陷产生合成致死作用

Chaoyang Sun ,Jun Yin ,Yong Fang ,Jian Chen ,Kang Jin Jeong ,Xiaohua Chen ,Christopher P Vellano ,Zhenlin Ju ,Wei Zhao ,Dong Zhang ,Yiling Lu ,Funda Meric-Bernstam ,Timothy A Yap ,Maureen Hattersley ,Mark J O'Connor ,Huawei Chen ,Stephen Fawell ,Shiaw-Yih Lin ,Guang Peng ,Gordon B Mills

BRD4 facilitates replication stress-induced DNA damage response

BRD4促进复制应激诱导的DNA损伤反应

Jingwen Zhang ,Austin M Dulak ,Maureen M Hattersley ,Brandon S Willis ,Jenni Nikkilä ,Anderson Wang ,Alan Lau ,Corinne Reimer ,Michael Zinda ,Stephen E Fawell ,Gordon B Mills ,Huawei Chen

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

BRD4 扩增促进高级别浆液性卵巢癌中的致癌基因表达程序并赋予对 BET 抑制剂的敏感性

Garrett W Rhyasen, Yi Yao, Jingwen Zhang, Austin Dulak, Lillian Castriotta, Kelly Jacques, Wei Zhao, Farzin Gharahdaghi, Maureen M Hattersley, Paul D Lyne, Edwin Clark, Michael Zinda, Stephen E Fawell, Gordon B Mills, Huawei Chen

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum

原发性弥漫性大B细胞淋巴瘤与复发/难治性弥漫性大B细胞淋巴瘤的比较分析揭示了突变谱的变化。

Greenawalt, Danielle M; Liang, Winnie S; Saif, Sakina; Johnson, Justin; Todorov, Petar; Dulak, Austin; Enriquez, Daniel; Halperin, Rebecca; Ahmed, Ambar; Saveliev, Vladislav; Carpten, John; Craig, David; Barrett, J Carl; Dougherty, Brian; Zinda, Michael; Fawell, Stephen; Dry, Jonathan R; Byth, Kate

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

针对携带 ER 突变的临床前内分泌抗性乳腺癌模型的有效联合疗法

Brendon Ladd, Anne Marie Mazzola, Teeru Bihani, Zhongwu Lai, James Bradford, Michael Collins, Evan Barry, Anne U Goeppert, Hazel M Weir, Kelly Hearne, Jonathan G Renshaw, Morvarid Mohseni, Elaine Hurt, Sanjoo Jalla, Haifeng Bao, Robert Hollingsworth, Corinne Reimer, Michael Zinda, Stephen Fawell, Ce